Jason M. Broderick

The OASIS trial is examining the capability of the RENOVA iStim implantable tibial neuromodulation system to reduce urinary urgency incontinence episodes.

The risk was decreased further with each additional chemotherapy cycle a patient received.

The ELITE study is exploring the InterStim Micro neurostimulator in patients with urinary urge incontinence, urinary frequency, non-obstructive urinary retention, and fecal incontinence.

Rucaparib pharmacokinetics in men with prostate cancer were comparable to those reported for women with ovarian cancer.

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

The ad hoc analysis also examined PSA response in the pivotal phase 3 ARAMIS trial.

The antibody-drug conjugate is used for the second-line treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma.

Under the Prescription Drug User Fee Act, the FDA is scheduled to make its decision on relugolix by December 20, 2020.

The positive findings could make nivolumab the new standard of care in the adjuvant setting for patients with muscle-invasive urothelial cancer.

A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical cold kit for the preparation of 68Ga-PSMA-11 injection for PET imaging in prostate cancer.

The Optilume drug-coated balloon catheter system has been approved for use in European patients with urethral strictures.

Updated results were also reported on other key end points, including time to pain progression, first symptomatic skeletal event, and initiation of chemotherapy.

Combination approach could overcome mechanisms that previously led to poor outcomes with single-agent checkpoint inhibition.

A new analysis supports return to widespread screening.

The results suggest the minimally-invasive procedure is an acceptable alternative to immediate surgery or radiation.

Smoking had a particularly strong impact on OAB risk in younger individuals.

Mark C. Markowski, MD, PhD, and Emmanuel S. Antonarakis, MD, provide potential explanations for the increased clinical activity of PARP inhibitors in BRCA2- versus BRCA1-mutated prostate cancer.

Personalized approach would reduce the number of biopsies some patients need to receive.

The overall risk of cardiac disorders was higher with abiraterone versus enzalutamide.

The FoundationOne Liquid CDx pan-tumor liquid biopsy examines over 300 cancer-related genes in a patient’s blood sample to inspect for deleterious alterations.

The combination improved overall survival versus sunitinib in patients with previously untreated advanced RCC.

Data from a pivotal trial showed the eCoin Peripheral Neurostimulator led to a clinically significant improvement in urgency urinary incontinence.

Investigators warn of the dangers of overprescribing antibiotics in cancer care.

Focal therapy using HIFU may be offered as an alternative to the existing modalities of treatment for select patients with all risk profiles of prostate cancer.

Starting radiotherapy up to 6 months following the start of androgen-deprivation therapy was not linked to poorer overall survival outcomes.

The new dose would reduce a patient’s required medical visits by 50%.

Findings from the phase 2 TRITON2 trial, which led to the FDA approval of the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer, have been published in the Journal of Clinical Oncology.

Response and survival rates with the immunotherapy-based regimen support ongoing phase 3 research with pembrolizumab in prostate cancer.

The randomized ESCALATE trial has a primary end point of symptomatic skeletal event-free survival.

The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.